Freenome

Freenome is an AI-driven biotechnology company based in South San Francisco, California, founded in 2014. The company focuses on developing blood-based early cancer detection tests using its proprietary multiomics platform, which integrates various biological data types to identify cancer at its earliest stages. Freenome's mission is to make cancer screening accessible and effective, aiming to detect cancer when it is most treatable. The company's primary product is its Early Cancer Detection Test, which currently targets colorectal cancer screening. Freenome is also working on detection solutions for other cancer types, including lung, prostate, breast, and pancreatic cancers. The technology has been clinically validated through studies and is preparing for FDA submission and commercialization. Freenome has raised $1.35 billion in funding and plans to go public through a merger in 2026, with future initiatives focused on expanding its testing capabilities and improving data integration.